0000000000154486

AUTHOR

Lucia Simoni

showing 9 related works from this author

The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in …

2017

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, pati…

MaleSex FactorRate ratio030226 pharmacology & pharmacyGonadal Steroid HormoneSeverity of Illness Index0302 clinical medicineOutpatient clinicAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; PsoriasisPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyGonadal Steroid HormonesOriginal ResearchIncidence (epidemiology)IncidenceMedicine (all)General MedicineMiddle AgedMenopausePostmenopauseItalyCyclosporineFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanAdultmedicine.medical_specialtyAdolescentAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult; Pharmacology (medical)Adverse drug reactionDermatology03 medical and health sciencesYoung AdultSex FactorsInternal medicineSeverity of illnessmedicineHumansPsoriasisRisk factorAdverse effectPsoriasibusiness.industryGendermedicine.diseaseSurgeryAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis; Medicine (all); Pharmacology (medical)Prospective StudiebusinessAdverse drug reaction; Cyclosporine; Dermatology; Female; Gender; Psoriasis;
researchProduct

The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study

2014

Background. The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). This post hoc analysis of DEEP study evaluates gender differences on WO and associated phenomena.Methods. Patients on dopaminergic treatment for ≥1 year were included in this multicenter observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well as the use of the 19-item wearing-off questionnaire (WOQ-19); WO was defined for scores ≥2. Post hoc analyses were conducted to investigate gender difference for demographic and clinical features …

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyLevodopaParkinson's diseaseArticle SubjectCross-sectional studylcsh:MedicineDiseaseAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Medicine (all); Biochemistry Genetics and Molecular Biology (all); 2300lcsh:TechnologySeverity of Illness IndexBiochemistryGeneral Biochemistry Genetics and Molecular BiologyAntiparkinson AgentsLevodopaSex FactorsRisk FactorsInternal medicinePost-hoc analysisSeverity of illnessBIO/14 FarmacologiamedicineHumansProspective cohort studylcsh:ScienceGaitGeneral Environmental ScienceAgedAged; Akathisia Drug-Induced; Antiparkinson Agents; Cross-Sectional Studies; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Severity of Illness Index; Sex Factors; Biochemistry Genetics and Molecular Biology (all); 2300; Medicine (all)2300business.industrylcsh:TMedicine (all)lcsh:RParkinson DiseaseGeneral Medicinemedicine.diseaseAkathisiaCross-Sectional StudiesDrug-InducedPhysical therapyObservational studylcsh:QFemalebusinessAkathisia Drug-InducedResearch Articlemedicine.drug
researchProduct

One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational St…

2021

Raffaele Antonelli Incalzi,1 Francesco Blasi,2,3 Nicola Scichilone,4 Alessandro Zullo,5 Lucia Simoni,5 Giorgio Walter Canonica6 On Behalf of STORICO study group1Internal Medicine and Geriatrics Department Biomedical Campus University of Rome, Rome, Italy; 2Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; 3Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 4DIBIMIS, University of Palermo, Palermo, Italy; 5Medineos Observational Research, Modena, Italy; 6Personalized Medicine Asthma & Allergy Clinic, Humanitas University, Humanitas &…

medicine.medical_specialtyphenotypeQuality of sleepHealth Statusquality of sleepSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseaseDisease cluster03 medical and health sciencesDiseases of the respiratory systemPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeInternal medicineSurveys and Questionnairesevolutionmedicinecohort studyHumansIn patient030212 general & internal medicineOriginal ResearchCOPDRC705-779business.industryreal worldCohort study Evolution Phenotype Quality of life Quality of sleep Real worldGeneral Medicinemedicine.disease030228 respiratory systemquality of lifecohort study.Multi dimensionalObservational studybusinessCohort studyFollow-Up StudiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Characterization of circadian COPD symptoms by phenotype: Methodology of the STORICO observational study

2017

Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. The symptoms of COPD are troublesome, variable, can occur during all parts of the 24-h day and have a substantial impact on patients' health status, quality of life and healthcare resource utilization. Reducing symptoms, improving health status and increasing physical activity are major goals in the management of stable COPD. In order to provide effective, patient-oriented care, patients should be evaluated on the basis of lung function, frequency of symptoms and patient-perceived impact of symptoms on their lives and treatment decisions made on a case-by-case basis. The …

Malemedicine.medical_specialtyPediatricsCross-sectional study24-Hour symptomLongitudinal StudieSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of life (healthcare)Surveys and QuestionnairesHealth careHealthcare resources utilizationmedicineInternal MedicineHumansCOPDSurveys and QuestionnaireRespiratory functionLongitudinal Studies030212 general & internal medicineIntensive care medicineCross-Sectional StudieCOPDbusiness.industrymedicine.diseaseComorbidityHealth-related quality of life (HRQoL)Circadian RhythmCross-Sectional StudiesPhenotype030228 respiratory systemItalyResearch DesignCohortDisease ProgressionQuality of LifeObservational studyFemalebusinessHuman
researchProduct

The COPD multi-dimensional phenotype: A new classification from the STORICO Italian observational study.

2019

BackgroundThis paper is aimed to (i) develop an innovative classification of COPD, multi-dimensional phenotype, based on a multidimensional assessment; (ii) describe the identified multi-dimensional phenotypes.MethodsAn exploratory factor analysis to identify the main classificatory variables and, then, a cluster analysis based on these variables were run to classify the COPD-diagnosed 514 patients enrolled in the STORICO (trial registration number: NCT03105999) study into multi-dimensional phenotypes.ResultsThe circadian rhythm of symptoms and health-related quality of life, but neither comorbidity nor respiratory function, qualified as primary classificatory variables. Five multidimension…

MalePulmonologyPhysiologyComorbidityAnxietyPathology and Laboratory MedicineCohort StudiesPulmonary Disease Chronic ObstructiveMathematical and Statistical TechniquesQuality of lifeMedicine and Health SciencesCoughingCluster AnalysisRespiratory functionPublic and Occupational HealthAged 80 and overCOPDMultidisciplinaryDepressionApplied MathematicsSimulation and ModelingQStatisticsRMiddle AgedExploratory factor analysisCircadian RhythmBody FluidsCircadian RhythmsPhenotypeItalyPhysical SciencesAnxietyMedicineFemalemedicine.symptomAnatomyFactor AnalysisAlgorithmsCohort studyResearch Articlemedicine.medical_specialtyScienceMemory EpisodicChronic Obstructive Pulmonary DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioResearch and Analysis MethodsClustering AlgorithmsSigns and SymptomsDiagnostic MedicineInternal medicinemedicineCOPDHumansStatistical MethodsAgedbusiness.industryBiology and Life SciencesPhysical Activitymedicine.diseaseComorbidityrespiratory tract diseasesMucusDyspneaCoughQuality of LifeObservational studybusinessFactor Analysis StatisticalSleepPhysiological ProcessesChronobiologymultiple phenotypesMathematicsPloS one
researchProduct

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study

2019

Background: Understanding the level of patients’ satisfaction with treatment and its determinants have the potential to impact therapeutic management and clinical outcome in chronic conditions such as chronic obstructive pulmonary disease (COPD). Methods: A national, multicenter, longitudinal, observational study of COPD from 20 Italian pulmonary centers to explore patients’ satisfaction to treatment [assessed by the Treatment Satisfaction Questionnaire, 9 items (TSQM-9)] and association with clinical parameters [including dyspnea score, COPD Assessment Test (CAT) score, exacerbation rate], adherence to treatment [Morisky Medication-Taking Adherence Scale (MMAS-4)], illness perception [eval…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyCOPD; adherence; treatment satisfactionPulmonary diseaseSocio-culturaleTreatment resultstreatment satisfactionSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome (game theory)Medication AdherencePulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesAdministration InhalationSettore MED/10MedicineHumansCOPDPharmacology (medical)030212 general & internal medicineadherenceIntensive care medicineOriginal ResearchAgedlcsh:RC705-779adherence COPD treatment satisfactionbusiness.industrylcsh:Diseases of the respiratory systemMiddle AgedDyspneaInhalation030228 respiratory systemItalyPatient SatisfactionAdministrationObservational studyFemalebusinessFollow-Up Studies
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Additional file 1 of Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic tr…

2022

Additional file 1: Socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis (in Secukinumab and TNFis patients). In this file main socio-demographic and clinical characteristics at enrollment/start of biologic treatment under analysis are described in the groups of patients treated with Secukinumab and with TNFis.

researchProduct

Additional file 1 of A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA obs…

2021

Additional file 1.

Data_FILES
researchProduct